Tokai appoints CMO and VP of medical development
This article was originally published in Scrip
Executive Summary
Tokai, a biopharmaceutical firm specialising in prostrate cancer treatments, has appointed Adrian M. Senderowicz as its chief medical officer and vice-president of medical development. Dr Senderowicz has previously served as medical director of oncology clinical development at AstraZeneca. In this role he oversaw the US FDA approval of Caprelsa (vandetanib) for advanced medullary thyroid carcinoma. Before joining AstraZeneca, he held various senior positions at the FDA Division of Oncology Drug Products in the Center for Drug Evaluation and Research. Tokai says that Dr Senderowicz brings valuable expertise to the development of its lead candidate, galeterone (TOK-001), which recently won an FDA fast-track designation from for metastatic castration-resistant prostate cancer.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.